How is glutathione regenerated?

Glutathione reductase converts GSSG back to two GSH molecules, using NADPH as the electron source.

Why NADPH rather than NADH?

The reductase is specific for the phosphorylated cofactor. That specificity is what keeps the anabolic and catabolic pools independent.

Does more glutathione mean more capacity?

Not necessarily. Regeneration requires NADPH, so a cell with abundant glutathione and depleted NADPH cannot restore its reduced pool.

NAD+

Two Products in This Catalogue, One Connected System

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Glutathione's antioxidant capacity depends on being regenerated after use, and glutathione reductase performs that regeneration using NADPH as the electron source. The two systems sold separately in this catalogue are parts of one connected chain.

Key facts

Reaction: GSSG + NADPH → 2 GSH
Enzyme: Glutathione reductase
Electron source: NADPH, not NADH
NADPH supplied largely by: Pentose phosphate pathway
Consequence: Glutathione capacity depends on NADPH supply
Pathway study: Jin 2018 (PMID 29351478)

Why glutathione needs regenerating

When glutathione donates electrons it becomes the oxidised disulfide GSSG. A cell whose glutathione had all converted to GSSG would have no reducing capacity left. Glutathione reductase converts it back, which is what makes the pool a renewable buffer rather than a consumable stock.

Where the electrons come from

NADPH. The reductase transfers electrons from NADPH to the disulfide bond, splitting GSSG back into two molecules of GSH. Specifically NADPH and not NADH — that is the phosphate distinction doing its work, and it places the whole glutathione system downstream of the NADP pool.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Which puts a limit somewhere unexpected

Glutathione's antioxidant capacity is limited by NADPH supply as much as by how much glutathione is present. A cell with abundant glutathione and depleted NADPH cannot regenerate it, so the pool converts to GSSG and stays there. Total glutathione is one number; usable glutathione depends on something else entirely.

Where NADPH itself comes from

Substantially from the pentose phosphate pathway, which diverts glucose specifically to produce it. Jin and colleagues examined pentose phosphate pathway activity in rat liver in 2018, finding it paralleled lipogenesis but not antioxidant processes — a reminder that NADPH serves biosynthesis and defence simultaneously and the two demands compete.

Why this connects two categories on this site

Glutathione and NAD+ are sold here as separate products with separate articles. Chemically they are links in one chain: glucose feeds the pentose phosphate pathway, which makes NADPH, which glutathione reductase uses to regenerate GSH. Nothing on this site previously drew that line, and it runs through NADP rather than NAD.

What none of this establishes

That supplying either molecule affects the other, or affects anything in a person. It describes a metabolic relationship established in biochemistry. Both are supplied here for laboratory research only, and no claim is made about antioxidant status or any condition in anyone.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How is glutathione regenerated?: Glutathione reductase converts GSSG back to two GSH molecules, using NADPH as the electron source.
Why NADPH rather than NADH?: The reductase is specific for the phosphorylated cofactor. That specificity is what keeps the anabolic and catabolic pools independent.
Does more glutathione mean more capacity?: Not necessarily. Regeneration requires NADPH, so a cell with abundant glutathione and depleted NADPH cannot restore its reduced pool.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum